ACTRIMS

AcronymDefinition
ACTRIMSAmericas Committee for Treatment and Research in Multiple Sclerosis (Canada and US)
References in periodicals archive ?
Biopharmaceutical company Clene Nanomedicine Inc Friday announced the presentation of data in the 'Cutting Edge Developments in MS Research' Session of the third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum held from 1-3 February in San Diego, California.
Miller, PhD, opens the CMSC & ACTRIMS Cooperative Meeting with a lecture entitled: “Tolerance Directed Immunotherapies Employing Biodegradable PLG Nanoparticles - The Future of MS Treatment,” on Wednesday, May 28th.
On the other side of the Atlantic, ACTRIMS focused on the search for biomarkers, or easy-to-read signs to diagnose MS or track the impact of treatment.
Proceedings of the MS Forum Symposium 15th ECTRIMS/4th ACTRIMS Joint Congress, Basel, 31-34.
- South San Francisco, California-based biotechnology company Genentech has presented new data on Ocrevus (ocrelizumab) at 7th Joint ECTRIMS ACTRIMS meeting in Paris, France that showcase clinical advances around underlying disease activity and disability progression in relapsing and progressive forms of multiple sclerosis, through the exploration of newly emerging endpoints and precision monitoring, the company said.
The National MS Society will also recognize World MS Day at the May meeting of the Consortium of MS Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in Atlanta.
The LACTRIMS 2008 congress will be held in Montreal, Canada together with its North American and European counterparts, ACTRIMS and ECTRIMS.
Poster session presented at the Second Joint Meeting of the Americas and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS and ECTRIMS), Baltimore, MD.
The meeting was sponsored by ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) and ECTRIMS (its European counterpart) in collaboration with the National MS Society, which orchestrated the conference.
(NASDAQ: CELG) presented detailed results from the phase III RADIANCE Part B trial evaluating the efficacy and safety of ozanimod versus a first-line treatment, Avonex (interferon beta-1a, IFN), in patients with relapsing multiple sclerosis (RMS) at MSParis2017 7th Joint ECTRIMS ACTRIMS meeting held in Paris, October 25-28, 2017, the company said.
The data is being presented today in two posters during Poster Session 1, from 15:30 - 17:00 CEST, at the 7th Joint ECTRIMS - ACTRIMS meeting in Paris, France.